Keros Therapeutics (KROS) Amortizatization of Intangibles (2019 - 2025)
Keros Therapeutics posted quarterly Amortizatization of Intangibles of $622000.0 for Q4 2025, up 8.74% year-on-year from $572000.0 in Q4 2024, and up 2.13% on a QoQ basis from $609000.0 in Q3 2025.
Keros Therapeutics (KROS) has 7 years of Amortizatization of Intangibles data on file, last reported at $622000.0 in Q4 2025.
- For the quarter ending Q4 2025, Amortizatization of Intangibles rose 8.74% year-over-year to $622000.0; the trailing twelve-month figure through Dec 2025 stood at $2.4 million (up 32.42% YoY), and the FY2025 full-year result was $2.4 million, up 32.42% from the prior year.
- Amortizatization of Intangibles for Q4 2025 stood at $622000.0, up from $609000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $622000.0 in Q4 2025 and bottomed at $99000.0 in Q1 2021.
- The 5-year median for Amortizatization of Intangibles is $340000.0 (2023), against an average of $362150.0.
- The widest annual swing landed in 2023, when Amortizatization of Intangibles surged 157.14%; it then slumped 35.06% in 2024.
- A 5-year view of Amortizatization of Intangibles shows it stood at $198000.0 in 2021, then soared by 62.12% to $321000.0 in 2022, then grew by 4.36% to $335000.0 in 2023, then jumped by 70.75% to $572000.0 in 2024, then increased by 8.74% to $622000.0 in 2025.
- The last three Amortizatization of Intangibles figures came in at $622000.0 (Q4 2025), $609000.0 (Q3 2025), and $595000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 13,267.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Keros Therapeutics | 403.85 Mn | 116.45 Mn | - | 622,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 622,000.00 |
| Dec 31, 2025 | 622,000.00 |
| Sep 30, 2025 | 609,000.00 |
| Sep 30, 2025 | 609,000.00 |
| Jun 30, 2025 | 595,000.00 |
| Jun 30, 2025 | 595,000.00 |
| Mar 31, 2025 | 584,000.00 |
| Mar 31, 2025 | 584,000.00 |
| Dec 31, 2024 | 572,000.00 |
| Dec 31, 2024 | 572,000.00 |
| Sep 30, 2024 | 563,000.00 |
| Sep 30, 2024 | 563,000.00 |
| Jun 30, 2024 | 346,000.00 |
| Jun 30, 2024 | 346,000.00 |
| Mar 31, 2024 | 339,000.00 |
| Mar 31, 2024 | 339,000.00 |
| Dec 31, 2023 | 335,000.00 |
| Dec 31, 2023 | 335,000.00 |
| Sep 30, 2023 | 341,000.00 |
| Sep 30, 2023 | 341,000.00 |
| Jun 30, 2023 | 354,000.00 |
| Jun 30, 2023 | 354,000.00 |
| Mar 31, 2023 | 522,000.00 |
| Mar 31, 2023 | 522,000.00 |
| Dec 31, 2022 | 321,000.00 |
| Dec 31, 2022 | 321,000.00 |
| Sep 30, 2022 | 211,000.00 |
| Sep 30, 2022 | 211,000.00 |
| Jun 30, 2022 | 206,000.00 |
| Jun 30, 2022 | 206,000.00 |
| Mar 31, 2022 | 203,000.00 |
| Mar 31, 2022 | 203,000.00 |
| Dec 31, 2021 | 198,000.00 |
| Dec 31, 2021 | 198,000.00 |
| Sep 30, 2021 | 120,000.00 |
| Sep 30, 2021 | 120,000.00 |
| Jun 30, 2021 | 103,000.00 |
| Jun 30, 2021 | 103,000.00 |
| Mar 31, 2021 | 99,000.00 |
| Mar 31, 2021 | 99,000.00 |
| Dec 31, 2020 | 98,000.00 |
| Dec 31, 2020 | 98,000.00 |
| Sep 30, 2020 | 49,000.00 |
| Sep 30, 2020 | 49,000.00 |
| Jun 30, 2020 | 91,000.00 |
| Jun 30, 2020 | 91,000.00 |
| Mar 31, 2020 | 89,000.00 |
| Mar 31, 2020 | 89,000.00 |
| Dec 31, 2019 | 788,000.00 |
| Dec 31, 2019 | 788,000.00 |
| Sep 30, 2019 | -645,000.00 |
| Sep 30, 2019 | -645,000.00 |
| Jun 30, 2019 | 38,000.00 |
| Jun 30, 2019 | 38,000.00 |
| Mar 31, 2019 | 49,000.00 |
| Mar 31, 2019 | 49,000.00 |